Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line furmonertinib 160 mg for EGFR-mutant advanced or metastatic NSCLC
ChiCTR2400086161Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Peking Union Medical College Hospital. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400086161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086161.